ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Octreotide

Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.

Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.

Drug pageOctreotide: every studyMany companies study it; this page follows only the 30 they lead. All 121 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 17, 200230 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis210 open or runningphase 4since Dec 17, 2002Nov 2, 1999none ahead
Keenova Therapeuticsits history only40 open or runningphase 3since Sep 30, 2008Sep 30, 2008none ahead
Chiesi Farmaceuticiits history only30 open or runningphase 3since Aug 5, 2011Aug 5, 2011none ahead
Ambrilia Biopharmaits history only10 open or runningphase 3since Mar 21, 2008Mar 21, 2008none ahead
Dauntless Pharmaceuticalsits history only10 open or runningphase 1since Jan 17, 2017Jan 17, 2017none ahead

Also a collaborator on its studies: Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 2, 1999.

  1. Jan 21, 2004Phase 4 study in ObesityNCT00076362 · 60 enrolled · United States
  2. Oct 14, 2004Phase 2 study in ObesityNCT00094146 · 160 enrolled · United States
  3. Aug 8, 2005Phase 3 study in AcromegalyNCT00128232 · 100 enrolled
  4. Sep 7, 2005Phase 2 study in Prostatic NeoplasmsNCT00166725 · 40 enrolled · Italy
  5. Sep 9, 20052 phase 3 studiesNCT00170742, NCT00225979
  6. Sep 13, 20052 phase 4 studiesNCT00171886, NCT00171613
  7. Oct 9, 2005Phase 4 study in AcromegalyNCT00242541 · 50 enrolled · Mexico
  8. Oct 14, 2005Phase 3 study in Carcinoma, HepatocellularNCT00241020 · 270 enrolled
  9. Jun 1, 20062 phase 2 studiesNCT00332969, NCT00332696
  10. Sep 6, 2006Phase 3 study in AcromegalyNCT00372697 · 28 enrolled · Italy
  11. Sep 13, 2006Phase 4 study in AcromegalyNCT00376064 · 20 enrolled · Germany
  12. Dec 21, 2007Phase 1 study in Irritable Bowel SyndromeNCT00584298 · 50 enrolled · United States, Canada, Sweden and more
  13. Dec 21, 2007Phase 3 study in Colorectal NeoplasmsNCT00582426 · 139 enrolled · Brazil
  14. May 15, 2008Phase 3 study in Carcinoid TumorNCT00690430 · 186 enrolled · United States, Argentina, Austria and more

TargetBeta

“Somatostatin receptor agonist”ChEMBL 37, by rule

Studies

All 21 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00690430Carcinoid Tumor · United States, Argentina, Austria and more3CompletedApr 2012186
NCT00584298Irritable Bowel Syndrome · United States, Canada, Sweden and more1CompletedApr 200950
NCT00582426Colorectal Neoplasms · Brazil3CompletedSep 2010139
NCT00376064Acromegaly · Germany4CompletedJan 201020
NCT00372697Acromegaly · Italy3CompletedOct 200728
NCT00332969Thymoma · Germany2CompletedOct 201025
NCT00332696Peritoneal Neoplasms · France2CompletedSep 200864
NCT00241020Carcinoma, Hepatocellular3CompletedOct 2005270
NCT00242541Acromegaly · Mexico4TerminatedAug 200550
NCT00225979Acromegaly3CompletedMar 2005100
NCT00171886Acromegaly · Spain4CompletedMay 200620
NCT00171613Sexual Infantilism4CompletedOct 200532
NCT00170742Disease · Switzerland3TerminatedMay 200617
NCT00166725Prostatic Neoplasms · Italy2Completed40
NCT00128232Acromegaly3CompletedAug 2004100
NCT00094146Obesity · United States2Completed160
NCT00076362Obesity · United States4CompletedJul 200560
NCT00050635Neoplasms · United States4Completed150
NCT00006269Colorectal Neoplasms · United States3TerminatedDec 199989
NCT00002253Diarrhea · United States–Completed
NCT00002252Diarrhea · United States–Completed

How it is read

Names in the registry

  • “Octreotide”, 9 entries
  • “Sandostatin LAR Depot”, 3 entries
  • “Octreotide LAR”, 3 entries
  • “Sandostatin LAR”, 3 entries
  • “Octreotide capsules”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.